192 related articles for article (PubMed ID: 31497246)
21. Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors.
Nakamura R; Fujii H; Yamada T; Matsui Y; Yaoi T; Honda M; Tanaka N; Miyagawa-Hayashino A; Yoshimura A; Morimoto K; Iwasaku M; Tokuda S; Kim YH; Konishi E; Itoh K; Takayama K
JTO Clin Res Rep; 2023 Jun; 4(6):100525. PubMed ID: 37426308
[TBL] [Abstract][Full Text] [Related]
22. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
23. LHX6 Affects Erlotinib Resistance and Migration of
Wang Q; Liao J; He Z; Su Y; Lin D; Xu L; Xu H; Lin J
Onco Targets Ther; 2020; 13():10983-10994. PubMed ID: 33149613
[TBL] [Abstract][Full Text] [Related]
24. The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated
Murakami Y; Sonoda K; Abe H; Watari K; Kusakabe D; Azuma K; Kawahara A; Akiba J; Oneyama C; Pachter JA; Sakai K; Nishio K; Kuwano M; Ono M
Oncotarget; 2017 Sep; 8(41):70736-70751. PubMed ID: 29050315
[TBL] [Abstract][Full Text] [Related]
25. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
26. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
[TBL] [Abstract][Full Text] [Related]
27. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
28. Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
Sun H; Ma H; Wang J; Xia L; Zhu G; Wang Z; Sun J; Chen Z
Tumour Biol; 2017 Jul; 39(7):1010428317709639. PubMed ID: 28714370
[TBL] [Abstract][Full Text] [Related]
29. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.
Lantermann AB; Chen D; McCutcheon K; Hoffman G; Frias E; Ruddy D; Rakiec D; Korn J; McAllister G; Stegmeier F; Meyer MJ; Sharma SV
Cancer Res; 2015 Nov; 75(22):4937-48. PubMed ID: 26490646
[TBL] [Abstract][Full Text] [Related]
31. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Serizawa M; Takahashi T; Yamamoto N; Koh Y
J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
[TBL] [Abstract][Full Text] [Related]
32. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
[TBL] [Abstract][Full Text] [Related]
33. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
35. Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Xia J; Bai H; Yan B; Li R; Shao M; Xiong L; Han B
Oncotarget; 2017 Dec; 8(65):108522-108533. PubMed ID: 29312548
[TBL] [Abstract][Full Text] [Related]
36. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
[TBL] [Abstract][Full Text] [Related]
37. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
39. Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
Hong SW; Park NS; Noh MH; Shim JA; Ahn BN; Kim YS; Kim D; Lee HK; Hur DY
Lung Cancer; 2017 Apr; 106():115-124. PubMed ID: 28285685
[TBL] [Abstract][Full Text] [Related]
40. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
Suda K; Mizuuchi H; Sato K; Takemoto T; Iwasaki T; Mitsudomi T
Int J Cancer; 2014 Aug; 135(4):1002-6. PubMed ID: 24458568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
